₹659.80
−1.98%NSE close, 16 Nov 2026
+415.87%
Bliss GVS Pharma is a small cap company, listed on NSE under the symbol BLISSGVS. At ₹659.80 a share, the market values the whole company at ₹7,012 crore.
In FY26, it reported sales of ₹927 crore and a net profit of ₹129 crore, an operating margin of 17.7%. Over the last three years, sales grew 7.4% a year and net profit grew 104.8% a year.
The market values the company at 43.5 times its profit over the last twelve months and 5.43 times its book value; its return on equity is 12.5% and it has almost no borrowings.
Promoters hold 50.07% of the shares, and have pledged 95.8% of their holding. Foreign institutions hold 5.03%, and domestic institutions, mutual funds among them, 9.62%.
Over the past year the share price has risen 334.1%, and it is 10.8% below its 52-week high.
₹ crore. Consolidated figures.
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI Listing Regulations )
Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Grant of Marketing Authorisation from MHRA, UK for Mesalazine 1g Suppositories
The outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019.
The financial results for the period ended September 30, 2026.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 | 313 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 213 | 183 | 213 | 209 | 233 |
| Operating profit | 43.7 | 28.4 | 34.3 | 41.5 | 29.8 | 21.1 | 41.3 | 31.8 | 34.8 | 44.4 | 76.4 | 80.6 |
| Operating margin | 21.8% | 14.3% | 18.7% | 19.1% | 14.2% | 10.7% | 19.9% | 13.0% | 15.9% | 17.3% | 26.8% | 25.7% |
| Other income | 5.4 | 5.6 | 4.1 | 5.0 | 15.3 | 12.1 | 35.5 | 20.2 | 18.5 | 11.2 | 9.6 | 8.3 |
| Interest | 2.1 | 1.9 | 1.5 | 3.8 | 1.1 | 1.7 | 5.5 | 3.0 | 1.5 | 2.0 | 0.6 | 3.3 |
| Depreciation | 7.0 | 6.9 | 6.9 | 7.0 | 7.6 | 8.0 | 8.2 | 8.3 | 8.4 | 8.7 | 9.9 | 10.5 |
| Profit before tax | 40.0 | −4.0 | 30.1 | 35.7 | 36.4 | 23.4 | 63.1 | 40.6 | 40.9 | 45.0 | 75.5 | 75.1 |
| Tax | 11.0 | 1.0 | 8.0 | 10.0 | 10.6 | 6.8 | 18.8 | 12.0 | 16.1 | 8.0 | 24.1 | 21.8 |
| Net profit | 27.6 | −9.2 | 20.7 | 24.3 | 23.8 | 15.5 | 43.0 | 27.3 | 23.3 | 35.6 | 50.1 | 52.3 |
| EPS (₹) | 2.64 | -0.88 | 1.97 | 2.31 | 2.27 | 1.47 | 4.08 | 2.58 | 2.20 | 3.37 | 4.73 | 4.92 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Sales | 898 | 689 | 577 | 747 | 770 | 810 | 927 |
| Expenses | 741 | 566 | 471 | 629 | 620 | 683 | 763 |
| Operating profit | 158 | 123 | 107 | 118 | 151 | 127 | 164 |
| Operating margin | 17.5% | 17.9% | 18.5% | 15.8% | 19.6% | 15.6% | 17.7% |
| Other income | 37.6 | 37.1 | 20.2 | 31.5 | 28.7 | 36.5 | 73.5 |
| Interest | 4.4 | 5.4 | 5.5 | 4.7 | 6.9 | 8.1 | 12.0 |
| Depreciation | 8.9 | 12.6 | 17.2 | 17.3 | 26.4 | 29.4 | 33.5 |
| Profit before tax | 182 | 129 | 104 | 54.2 | 117 | 126 | 190 |
| Tax | 55.3 | 33.7 | 30.2 | 31.0 | 35.3 | 35.4 | 54.9 |
| Net profit | 134 | 97.3 | 68.5 | 15.0 | 75.5 | 84.3 | 129 |
| EPS (₹) | 11.99 | 9.43 | 6.64 | 1.46 | 7.23 | 8.02 | 12.23 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 135 | 106 | 139 | 35.7 |
| From investing | −93.0 | −75.4 | −38.3 | −15.0 |
| From financing | −23.7 | −30.3 | −89.2 | −18.8 |
| Spent on fixed assets | 0 | −76.1 | −56.8 | −31.7 |
| Free cash flow | 135 | 29.8 | 81.9 | 4.0 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | 14.9% | 14.1% | 11.9% | 2.0% | 9.8% | 10.4% | 13.9% |
| Operating margin | 17.5% | 17.9% | 18.5% | 15.8% | 19.6% | 15.6% | 17.7% |
| Return on equity | – | – | – | – | 7.8% | 8.0% | 10.8% |
| Return on capital employed | – | – | – | – | 11.7% | 11.9% | 16.9% |
| Return on assets | – | – | – | – | 6.2% | 6.5% | 8.7% |
| Debt to equity | – | – | – | – | 0.09 | 0.07 | 0.00 |
| Interest coverage | 42.20 | 24.80 | 19.90 | 12.40 | 17.90 | 16.50 | 16.80 |
| Debt to assets | – | – | – | – | 0.07 | 0.05 | 0.00 |
| Current ratio | – | – | – | – | 5.08 | 4.77 | 4.02 |
| Quick ratio | – | – | – | – | 4.34 | 4.04 | 3.38 |
| Cash ratio | – | – | – | – | 0.14 | 0.14 | 0.15 |
| Asset turnover | – | – | – | – | 0.63 | 0.62 | 0.62 |
| Fixed asset turnover | – | – | – | – | 2.13 | 2.04 | 2.06 |
| Inventory turnover | – | – | – | – | 3.20 | 3.30 | 2.80 |
| Receivables turnover | – | – | – | – | 1.90 | 1.80 | 1.80 |
| Gross margin | – | – | – | – | 50.4% | 48.9% | 54.2% |
| Cash from operations to profit | – | – | – | 901.0% | – | 126.0% | 107.0% |
| Effective tax rate | 30.4% | 26.1% | 29.0% | 57.3% | 30.2% | 28.2% | 28.9% |
Notice of Postal Ballot dated October 01, 2026 ("Notice") alongwith the Explanatory Statement for seeking approval of the members of the Company by way of remote e-voting to transact the Special Business as set out in the Notice
The Postal Ballot Notice dated September 28, 2026 ("Notice") alongwith the Explanatory Statement for seeking approval of the members of the Company by way of remote e-voting to transact the Special businesses as set out in the Notice
Allotment of 53500 Shares.
Disclosure Submitted to Stock Exchanges on September 28, 2026 under Regulation 31A(10) of the SEBI Listing Regulations in relation to re-classification from the promoter and promoter group category to the public category.
Outcome of Board Meeting held on October 01, 2026.
Outcome of the 2nd Board Meeting held on September 28, 2026 at shorter Notice regarding re-classification from the "Promoter and Promoter Group" category to the "public" category.
Change in Management pursuant to the Change in Control of the Company.
Outcome of Board Meeting held on September 28, 2026 relating to the consummation of the transaction contemplated in the share purchase agreement dated May 23, 2026
A copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
The ESOP Allotment Committee of the Company at its meeting held today i.e. September 04,2026 has approved the allotment of 55,250 equity shares of the face value Re 1/- to the eligible employees who have exercised their stock options under the Bliss GVS Pharma Limited-…